JP2022515720A5 - - Google Patents

Info

Publication number
JP2022515720A5
JP2022515720A5 JP2021534203A JP2021534203A JP2022515720A5 JP 2022515720 A5 JP2022515720 A5 JP 2022515720A5 JP 2021534203 A JP2021534203 A JP 2021534203A JP 2021534203 A JP2021534203 A JP 2021534203A JP 2022515720 A5 JP2022515720 A5 JP 2022515720A5
Authority
JP
Japan
Prior art keywords
sequence
referred
sar
peptide ligand
cysteine residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021534203A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515720A (ja
Filing date
Publication date
Priority claimed from GBGB1820316.6A external-priority patent/GB201820316D0/en
Application filed filed Critical
Publication of JP2022515720A publication Critical patent/JP2022515720A/ja
Publication of JP2022515720A5 publication Critical patent/JP2022515720A5/ja
Pending legal-status Critical Current

Links

JP2021534203A 2018-12-13 2019-12-13 Il-17に特異的な二環式ペプチドリガンド Pending JP2022515720A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1820316.6A GB201820316D0 (en) 2018-12-13 2018-12-13 Bicyclic peptide ligands specific for IL-17
GB1820316.6 2018-12-13
PCT/GB2019/053534 WO2020120978A1 (en) 2018-12-13 2019-12-13 Bicyclic peptide ligands specific for il-17

Publications (2)

Publication Number Publication Date
JP2022515720A JP2022515720A (ja) 2022-02-22
JP2022515720A5 true JP2022515720A5 (cg-RX-API-DMAC7.html) 2022-12-19

Family

ID=65146974

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534203A Pending JP2022515720A (ja) 2018-12-13 2019-12-13 Il-17に特異的な二環式ペプチドリガンド

Country Status (6)

Country Link
US (1) US20220024983A1 (cg-RX-API-DMAC7.html)
EP (1) EP3894007A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022515720A (cg-RX-API-DMAC7.html)
CN (1) CN113474046A (cg-RX-API-DMAC7.html)
GB (1) GB201820316D0 (cg-RX-API-DMAC7.html)
WO (1) WO2020120978A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021006421A (es) 2018-12-19 2021-08-16 Leo Pharma As Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
GB201918559D0 (en) * 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB201918558D0 (en) * 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
EP4077349A1 (en) * 2019-12-16 2022-10-26 BicycleTX Limited Bicyclic peptide ligands specific for il-17
GB201918557D0 (en) * 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
JP7664947B2 (ja) 2020-04-30 2025-04-18 ヤンセン ファーマシューティカ エヌ.ベー. Il-17の調節因子としてのイミダゾリダジン

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
ES2428869T3 (es) 2005-01-24 2013-11-12 Pepscan Systems B.V. Compuestos de unión, compuestos inmunógenos y peptidomiméticos
PL1963368T6 (pl) 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
JP6074574B2 (ja) 2008-02-05 2017-02-08 バイシクル セラピューティクス リミテッド 方法及び組成物
US20110223169A1 (en) 2008-11-26 2011-09-15 Stern Michael E Il-17 antibody inhibitor for treating dry eye
WO2011141823A2 (en) 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
WO2011163452A2 (en) 2010-06-24 2011-12-29 Eleven Biotherapeutics, Inc. Treating surface of the eye disorders
NZ731185A (en) * 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
EP3181146A1 (en) * 2015-12-16 2017-06-21 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors
GB201600911D0 (en) * 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Stabilized peptide derivatives
GB201810327D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17

Similar Documents

Publication Publication Date Title
JP2022514255A5 (cg-RX-API-DMAC7.html)
JP2022517442A5 (cg-RX-API-DMAC7.html)
JP2022512478A5 (cg-RX-API-DMAC7.html)
JP2022518695A5 (cg-RX-API-DMAC7.html)
JP2022517040A5 (cg-RX-API-DMAC7.html)
JP2022513223A5 (cg-RX-API-DMAC7.html)
JP2022514687A5 (cg-RX-API-DMAC7.html)
JP2022517399A5 (cg-RX-API-DMAC7.html)
JP2022544058A5 (cg-RX-API-DMAC7.html)
JP2022532134A5 (cg-RX-API-DMAC7.html)
JP2022542291A5 (cg-RX-API-DMAC7.html)
JP2022518210A5 (cg-RX-API-DMAC7.html)
JP2022514618A5 (cg-RX-API-DMAC7.html)
JP2022552839A5 (cg-RX-API-DMAC7.html)
FI3294345T3 (fi) Tpp1-formulaatioita ja menetelmiä cln2-taudin hoitamiseksi
FI3746467T3 (fi) Muutetut lipidoidut relaksiinin b-ketjun peptidit ja niiden terapeuttinen käyttö
JP2012506442A5 (cg-RX-API-DMAC7.html)
JP2006514104A5 (cg-RX-API-DMAC7.html)
EP2326341A2 (en) Peptide formulations and uses thereof
JP2006506942A5 (cg-RX-API-DMAC7.html)
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
WO2015179691A9 (en) Cell penetrating peptides and methods of making and using thereof
JP2007534698A5 (cg-RX-API-DMAC7.html)
KR20100056479A (ko) 제어 방출 인터페론 약물 제품 및 이를 사용한 hcv 감염의 치료
JP2023549229A5 (cg-RX-API-DMAC7.html)